Study: The immune system for the elderly responds well to cancer medicine

A recent study has shown that the elderly with cancer respond well to its strong new medicine, despite the age -related changes that make their immune system less effective. Daniel Zabranski of the University of Jones Hopkins said in a statement. The researchers team analyzed the indicators of the immune system in the blood samples of nearly 100 cancer patients treated with immune barriers, and almost half of it at the age of at least 65 years. The immunotherapy medicine is widely used for the effect of protein that works “checkpoints”, or a hindrance before the reaction of the immune system. ‘Brakes’ for the immune system and practically the medicine is launched ‘brakes’ for the immune system, which allows T -cells to identify and attack cancer cells more effectively. Among the medicine, “Citeroda” was produced by the company “Merck and Co”, and also “Obdivo” of the “Bristol Myers Square” and “Tesenterick” of “Roche”. The study, published in the “Nature Communicichens” magazine, showed that both young and older patients benefited from the treatment pit. This is achieved in older patients, despite the decline in production and natural activity of inflammatory protein compounds, known as cytokines or their weakness. The older patients also had fewer immune cells, but ‘worn’, known as ‘naive’ t -cells. The researchers note that the ‘Talcean exhaustion’ they have seen in older patients is indeed the purpose of experimental cancer medicine in the process of research. They said that such medicine is called medicine that develops the naive T -cells, which are developed by companies such as “Roche”, “Bristol Maires” and Estrazzinica, can provide a greater potential benefit to the elderly.